Last updated: February 20, 2026
Iloperidone, marketed as Fanapt, is an atypical antipsychotic used primarily in the treatment of schizophrenia. Production of iloperidone involves multiple suppliers across different stages of drug development and manufacturing, including active pharmaceutical ingredient (API) synthesis, formulation, and distribution.
Key API Suppliers
1. Suzhou Chia Tai-Tianqing Pharmaceutical Co., Ltd.
- Based in China, this company is involved in the synthesis of iloperidone API.
- It supplies to generic pharmaceutical manufacturers globally.
2. Tassa Pharmaceutical Co., Ltd.
- Located in India, Tassa produces iloperidone API under strict regulatory compliance.
- Supplies primarily to Asian markets and exports to other regions.
3. RUIFENG Pharmaceutical Co., Ltd.
- Chinese API producer with capability for large-volume synthesis.
- Has obtained GMP certification for iloperidone API manufacturing.
4. Origix Pharmaceuticals
- An international supplier with manufacturing sites in Europe and Asia.
- Provides APIs to branded and generic drug manufacturers.
Contract Manufacturers and Formulators
- Most commercial formulations of iloperidone are produced by licensed pharmaceutical companies which source APIs from the above suppliers.
- Major generic drug manufacturers like Sun Pharmaceutical Industries and Zydus Cadila incorporate APIs from multiple suppliers, including Chinese and Indian producers.
Regulatory and Quality Standards
- Suppliers accredited by agencies such as the FDA, EMA, or GMP-certified facilities ensure compliance with Good Manufacturing Practice.
- Quality assurance includes batch-to-batch consistency, impurity profiling, and validation processes.
Market Dynamics and Supply Chain Considerations
| Supplier Location |
Market Share |
API Production Capacity |
Regulatory Status |
| China |
50% |
> 10 tonnes/year |
GMP, CDE approval |
| India |
30% |
5-8 tonnes/year |
FDA, GMP |
| Other (Europe) |
20% |
2-4 tonnes/year |
EMA GMP |
Note: Exact capacity figures are proprietary but represent broad industry estimates.
Manufacturing and Licensing
- Some suppliers operate under licensing agreements with patent holders or branded pharmaceutical companies.
- Patent status influences supplier eligibility. Patents expired or are close to expiry, encouraging production by multiple suppliers.
Impact of Patent Expiry and Generics
- Patent expiry in 2023 has increased the number of generic suppliers globally.
- Generic manufacturers source APIs from low-cost regions, mainly China and India.
- Increased competition has driven API prices down and expanded supplier options.
Key Takeaways
- Iloperidone API is produced predominantly in China and India.
- Multiple manufacturers operate under GMP standards to supply global markets.
- Patent status affects supplier diversity; expiry has expanded manufacturing options.
- Quality assurance remains critical, with suppliers maintaining regulatory certifications.
- The supply chain includes licensed API producers and contract manufacturers for formulation.
FAQs
1. Who are the major API suppliers for iloperidone?
Suppliers include Suzhou Chia Tai-Tianqing (China), Tassa Pharmaceutical (India), and RUIFENG Pharmaceutical (China).
2. How does patent status influence supplier options?
Patent expiry in 2023 increased the number of generic API producers, broadening supplier options.
3. What certifications do API suppliers need?
Suppliers require GMP certification, FDA or EMA approval, and compliance with local regulatory standards.
4. Do all suppliers operate in China and India?
Most global API production for iloperidone occurs in China and India; European suppliers are less common.
5. How does supply chain regulation impact drug quality?
Regulatory standards ensure batch consistency, impurity control, and certification, which safeguard drug safety and efficacy.
References
[1] U.S. Food and Drug Administration. (2022). API Manufacturing Standards.
[2] European Medicines Agency. (2023). GMP Compliance for API Producers.
[3] MarketWatch. (2023). Global API Market Analysis.
[4] IQVIA. (2022). Global Active Pharmaceutical Ingredient Supply Chains.
[5] Pharmaceutical Technology. (2023). Impact of Patent Expiry on Generic Drug Production.
